Compare Advanced Micro Devices (AMD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Twist Bioscience Corp — how do they compare? Advanced Micro Devices trades at $473.45 (market cap $766.54B), while Twist Bioscience Corp trades at $122.96 (market cap $7.82B). The key difference: Advanced Micro Devices is far larger — about 98× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Advanced Micro Devices nearer its low. Which is the better fit depends on your goals.
| AMD | TWST | |
|---|---|---|
Market Cap | $766.54B | $7.82B |
Sector | Technology | Health |
52-Week High | $580.91 | $124.88 |
52-Week Low | $151.14 | $24.16 |
Enterprise Value | $757.71B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $483.36, down 1.21% on the day, near its pivot point of $487 with support at $473 and resistance at $497. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $1.66 versus $1.62 expected, and revenue growth accelerating to $34.64 billion in 2025 from $25.8 billion in 2024. Operating cash flow surged to $7.71 billion in 2025, supporting investments in AI and data center segments. Technical indicators are neutral overall, with RSI levels suggesting balanced momentum.
Outlook remains positive driven by AI demand and market share gains, but high valuation multiples pose risks. Analyst consensus is bullish with a $615.11 price target, though competition and execution challenges warrant caution. The stock offers growth exposure but requires monitoring of competitive dynamics and margin sustainability.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
